2
First pocket inhaler for Covid-19 and other viral mutations
plus
Actualités sur Pharma
DEBIOPHARM AND GENOME & COMPANY JOIN FORCES TO CREATE NEW HIGHLY SPECIFIC THERAPIES FOR CANCER PATIENTS
Lausanne, Switzerland and Seongnam-si Gyeonggi-do, Republic of Korea (ots) - Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates Genome & Company (314130, CEO: Jisoo Pae, Hansoo Park), a global leading ...
plusNLS Pharmaceutics Ltd. Announces Pricing of $20.0 Million Initial Public Offering
Stans, Switzerland (ots) - NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces the pricing of its initial public offering of 4,819,277 units at a price of ...
plusForaCare Suisse AG releases Rapid COVID-19 Antigen Test / Test Results in 15 Minutes, No Laboratory Processing Required, Highly Accurate & Reliable Results
ST. GALLEN, Switzerland (ots) - ForaCare Suisse AG announced the release of its antigen test, FORA COVID-19 Antigen Rapid Test, that provides fast, accurate and easy-to-interpret test results. The test can be administered by trained professionals and doesn’t rely on laboratory-processing. Approved by Swissmedic, ...
plusRoche teams up with Diabeloop to advance the management of insulin pump therapy
Basel (ots) - - The partnership will create new opportunities to lower the burden for people with diabetes in daily therapy management and to improve therapy outcomes(1). - By partnering with Diabeloop, Roche steps into the field of automated insulin delivery (AID) representing a milestone in Roche's strategy of integrated Personalised Diabetes Management (iPDM). Roche ...
plusDebiopharm and the Japanese Cancer Association Announce Winners of the 2020 JCA-Mauvernay Award
Lausanne (ots) - For its sixteenth edition, the JCA-Mauvernay Award was awarded to Doctor Hideaki Ogiwara and Doctor Keisuke Kataoka Debiopharm (www.debiopharm.com), a Swiss-based global, biopharmaceutical company, presented the JCA-Mauvernay Award on October 3rd to Dr. Hideaki Ogiwara from the Division of Cancer Therapeutics of the National Cancer Center Research ...
plus
DEBIOPHARM TO PRESENT LATE BREAKING HEAD & NECK CANCER ABSTRACT AT THE 2020 EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS
Lausanne, Switzerland (ots) - Debiopharm announces the presentation of the 3-year phase II follow-up data along with 2 posters for xevinapant (antagonist of IAP -Inhibitor of Apoptosis Proteins) and WEE1 inhibitor Debio 0123 Debiopharm, ...
Un documentplusMSD (Merck Sharp & Dohme AG) Switzerland appoints Ans Heirman, Ph.D. as the new Managing Director of MSD Switzerland, effective September 1st, 2020
Un documentplusDEBIOPHARM'S NEW GENERATION RADIONUCLIDE THERAPY ADVANCES INTO CLINICAL RESEARCH IN THE FIGHT AGAINST LUNG CANCER
Lausanne (ots) - First patient dosed in the phase I small cell lung cancer (SCLC) trial with Debio 1124, a molecular-targeted radiotherapy Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, today announced the first patient dosed in the multicenter, single-arm, open-label Phase 1 study ...
plusNUCLEAI SECURED $6.5M SERIES-A INITIAL CLOSING LED BY DEBIOPHARM TO ADVANCE AI-POWERED PRECISION ONCOLOGY PLATFORM
Tel Aviv, Israel, Lausanne, Switzerland (ots) - - Nucleai, a computational biology company providing an AI-powered precision oncology platform for research and treatment decisions, secured $6.5M Series A initial closing. - Debiopharm's strategic corporate venture capital fund led the round joined by existing ...
plusIgNova files patent application on antibody against COVID-19
Visbek, Germany (ots) - IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (IgY). The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the ...
plusDebiopharm partners with Verity Pharmaceuticals for the exclusive US commercialization of Trelstar® for Prostate Cancer
LAUSANNE, SWITZERLAND & WAYNE, PENNSYLVANIA (ots) - Debiopharm, a Swiss-based, biopharmaceutical company, and Verity Pharmaceuticals Inc., a US based specialty pharmaceutical company focused on therapeutic solutions for genitourinary (GU) diseases, today announced having entered into an exclusive agreement that ...
plus
Acquisition of Debiopharm's investment portfolio company Kaiku Health broadens patient access to digital oncology intervention
Lausanne, Switzerland (ots) - - Debiopharm announces successful exit deal for Kaiku Health, a Finnish start-up specializing in digital solutions for improved patient outcomes and experience - Kaiku's acquisition by the Swedish company Elekta allows thousands of cancer treatment centers to gain access to the ...
plusMSD in Switzerland launches new gender-neutral parental leave policy effective February 1st, 2020
Lucerne (ots) - Following its nomination for an eight time in a row as Top Employer Switzerland, MSD (Merck Sharp & Dohme AG) is delighted to announce the introduction of a new gender-neutral parental leave policy to all its employees within ...
Un documentplusOn World Cancer Day, MSD Switzerland Stands United in Support of its Patients
Lucerne (ots) - World Cancer Day every 4th of February is a global uniting movement led by the Union for International Cancer Control (UICC). MSD (Merck Sharp & Dohme) is a proud sponsor of this initiative, joining the conversation to create a groundswell of awareness and action that will enable powerful ...
Un documentplusSwissmedic grants approval for pembrolizumab (KEYTRUDA®) in combination with axitinib (Inlyta®) for first-line therapy of advanced renal cell carcinoma(1)
Lucerne (ots) - - Swissmedic approval is based on a significant benefit in overall survival with pembrolizumab in combination with axitinib compared to sunitinib in the Phase III study KEYNOTE-426 - Pembrolizumab is the first PD-1 inhibitor that has ...
Un documentplusNovadiscovery raises series A financing to scale its in silico clinical trial platform - Debiopharm leads the round with EUR 5 million
Lausanne (ots) - - Novadiscovery pioneers the use of in silico clinical trials to predict drug efficacy and optimize clinical development, an approach meeting the strong expectations from pharmaceutical companies for faster and more efficient development, and benefiting from increased endorsement from health ...
plusKnight Partners with Debiopharm for the Commercialization of Trelstar® in Canada
MONTREAL, CANADA and LAUSANNE, SWITZERLAND (ots) - Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company and Debiopharm, a swiss-based, global biopharmaceutical company, today announced that they have entered into an exclusive agreement that grants Knight the rights to commercialize Trelstar® (triptorelin) in Canada. ...
plus
ForaCare Suisse AG Launches "Lab in the Pocket" Technology
ST. GALLEN, Switzerland (ots) - Innovative FORA 6 GTel Capability Provides 6 Tests with Single Device, SIM Direct-to-Telehealth Connectivity ForaCare Suisse AG announced the launch of its FORA 6 GTel multi-functional monitoring device with its new "Lab in the Pocket" technology (available on the GTel model and FORA 6 Series products). The innovative 6-in-1 monitoring technology provides seamless 3G/4G data transmission of ...
plusQuality-related problems concerning the prescription of medication / Helsana Drug Report
Zurich (ots) - The medication costs in Switzerland amounted to about CHF 7.6 billion in 2018. Since 2010, costs have risen by 46 percent, whereby half of this increase was attributable to immunosuppressants and cancer medication. Great savings potential is above all associated with the use of biosimilars. One of the other findings of this year's Helsana Drug Report is ...
plusCroma-Pharma GmbH expands its portfolio introducing elureTM / Croma complements its skincare portfolio with the advanced skin brightening solution elureTM.
Leobendorf (ots) - Croma is always committed to deepening its product portfolio to support customers in their daily work. With the acquisition of elure's distribution rights in its strategic markets, Croma can now offer an attractive new skincare that specifically addresses hyperpigmentation with a unique mode of ...
plusVersameb raises CHF 6.4 million in Seed C round and strengthens the team
plusA pancreatic and colorectal cancer trial initiated to address the needs of patients with Immune Checkpoint Inhibitor-resistant disease by combining IAP antagonist Debio 1143 with Keytruda®
Lausanne (ots) - First patient enrolled in the investigator initiated CATRIPCA study (Combination with an IAP Antagonist To Reverse Immune resistance in Pancreatic and Colorectal Adenocarcinoma) at the Léon Bérard Cancer Center in Lyon France Debiopharm (www.debiopharm.com) announced today the first patient ...
plusDebiopharm successfully completes randomized Phase II study for IAP antagonist Debio 1143 in high risk head & neck cancer patients
Lausanne, Switzerland (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced positive topline results across clinical endpoints following the completion of the two-year follow-up period of its double-blind, randomized Phase II study of Debio 1143 in high-risk, previously untreated ...
plus
Debiopharm and BIOASTER join forces to expand research to combat infectious diseases
Lausanne, Switzerland and Lyon, France (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, and BIOASTER (www.bioaster.org), the French Technology Research Institute in infectiology and microbiology, announced today having officialized a broad research agreement for the development of diagnostic and management innovation for infectious diseases. ...
plusDebiopharm expands its Immuno-Oncology development program for Debio 1143, with the first IAP inhibitor/nivolumab combination trial
Lausanne, Switzerland (ots) - First patient enrolled in SMARTPLUS-106, a Phase lb/II study in patients failing prior PD-1/PD-L1 treatment in selected solid tumors Debiopharm (www.debiopharm.com) announced today the first patient enrolled in SMARTPLUS-106, an exploratory study investigating the safety and efficacy of ...
plusMedical technology sector suffers from legal uncertainty / Swiss Medtech gives recommendation to Swiss medical device manufacturers
plusMicreos Raises EUR30 Million for Endolysin Technology Set to Replace Antibiotics / Funding for clinical development program XZ.700 and Gladskin Eczema USA launch
THE HAGUE, Netherlands (ots) - Dutch biotechnology company Micreos announced it has secured EUR30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its ...
plusGenePOC obtains FDA clearance for its GenePOC(TM) Strep A test in the US
Québec, Canada (ots) - GenePOC Inc., member of the Debiopharm Group, announces its third test to be cleared by the FDA, the GenePOC Strep A assay, to be used with the revogene(TM) device. About Group A Streptococcus (GAS) infection GAS is the most common bacterial etiology of pharyngitis accounting for 15 to 30% cases in children and 5 to 20% in adults[1]. In the ...
plus- 2
ForaCare Suisse AG forms service-oriented partnership with B. Braun
plus
Précédent12345678910Suivant